Alumis reports Q3 net loss of $93.1M; cash of $361.9M funds operations into 2026

ALUMIS INC.

2024-Q3 EPS reported -$10.15

Net loss of $93.1M in Q3 2024 vs $43.4M in Q3 2023; R&D expenses rose to $87.8M from $37.8M, including $23M milestone payment for FronThera acquisition.
Cash and marketable securities of $361.9M as of Sept 30, 2024, expected to fund operations into 2026.
ESK-001 Phase 3 ONWARD psoriasis trials on track; topline results expected H1 2026. Phase 2b SLE data expected 2026.
A-005 Phase 1 data expected by year-end 2024; Phase 2 MS trial initiation planned 2025.
Presented EADV data: ESK-001 40mg BID achieved 93% PASI 75 at 28 weeks (observed); supports ongoing Phase 3 dose.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.